Measuring Substance-Related Disorders Using Canadian Administrative Health Databanks: Interprovincial Comparisons of Recorded Diagnostic Rates, Incidence Proportions and Mortality Rate Ratios.

Canada alcohol-related disorders healthcare administrative claims international classification of diseases premature mortality substance-related disorders

Journal

Canadian journal of psychiatry. Revue canadienne de psychiatrie
ISSN: 1497-0015
Titre abrégé: Can J Psychiatry
Pays: United States
ID NLM: 7904187

Informations de publication

Date de publication:
02 2022
Historique:
pubmed: 28 9 2021
medline: 7 4 2022
entrez: 27 9 2021
Statut: ppublish

Résumé

Assessing temporal changes in the recorded diagnostic rates, incidence proportions, and health outcomes of substance-related disorders (SRD) can inform public health policymakers in reducing harms associated with alcohol and other drugs. To report the annual and cumulative recorded diagnostic rates and incidence proportions of SRD, as well as mortality rate ratios (MRRs) by cause of death among this group in Canada, according to their province of residence. Analyses were performed on linked administrative health databases (AHD; physician claims, hospitalizations, and vital statistics) in five Canadian provinces (Alberta, Manitoba, Ontario, Québec, and Nova Scotia). Canadians 12 years and older and registered for their provincial healthcare coverage were included. The International Classification of Diseases (ICD-9 or ICD-10 codes) was used for case identification of SRD from April 2001 to March 2018. During the study period, the annual recorded SRD diagnostic rates increased in Alberta (2001-2002: 8.0‰; 2017-2018: 12.8‰), Ontario (2001-2002: 11.5‰; 2017-2018: 14.4‰), and Nova Scotia (2001-2002: 6.4‰; 2017-2018: 12.7‰), but remained stable in Manitoba (2001-2002: 5.5‰; 2017-2018: 5.4‰) and Québec (2001-2002 and 2017-2018: 7.5‰). Cumulative recorded SRD diagnostic rates increased steadily for all provinces. Recorded incidence proportions increased significantly in Alberta (2001-2002: 4.5‰; 2017-2018: 5.0‰) and Nova Scotia (2001-2002: 3.3‰; 2017-2018: 3.8‰), but significantly decreased in Ontario (2001-2002: 6.2‰; 2017-2018: 4.7‰), Québec (2001-2002: 4.1‰; 2017-2018: 3.2‰) and Manitoba (2001-2002: 2.7‰; 2017-2018: 2.0‰). For almost all causes of death, a higher MRR was found among individuals with recorded SRD than in the general population. The causes of death in 2015-2016 with the highest MRR for SRD individuals were SRD, suicide, and non-suicide trauma in Alberta, Ontario, Manitoba, and Québec. Linked AHD covering almost the entire population can be useful to monitor the medical service trends of SRD and, therefore, guide health services planning in Canadian provinces.

Identifiants

pubmed: 34569874
doi: 10.1177/07067437211043446
pmc: PMC8978214
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-129

Références

Lancet. 2019 Nov 16;394(10211):1827-1835
pubmed: 31668728
CMAJ. 2012 Jan 10;184(1):49-53
pubmed: 21670117
Health Serv Res. 2008 Aug;43(4):1424-41
pubmed: 18756617
Acta Psychiatr Scand. 2015 Apr;131(4):297-306
pubmed: 25243359
BMC Health Serv Res. 2012 Jun 10;12:149
pubmed: 22682405
Sante Ment Que. 2018 Fall;43(2):39-64
pubmed: 32338685
Can J Psychiatry. 2009 Aug;54(8):571-5
pubmed: 19726010
Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):943-50
pubmed: 26114918
Can J Public Health. 2018 Apr;109(2):164-173
pubmed: 29981040
PLoS One. 2016 Mar 24;11(3):e0152223
pubmed: 27010534
Can J Cardiol. 2012 Mar-Apr;28(2):152-4
pubmed: 22301469
Lancet Psychiatry. 2016 Mar;3(3):280-96
pubmed: 26905481
Public Health Rep. 2018 Jul/Aug;133(4):360-365
pubmed: 29746207
World Psychiatry. 2014 Jun;13(2):153-60
pubmed: 24890068
BMC Health Serv Res. 2012 Jan 23;12:18
pubmed: 22270080
Eur J Public Health. 2006 Apr;16(2):198-202
pubmed: 16157612
PLoS One. 2020 Jan 15;15(1):e0226732
pubmed: 31940370
Drug Alcohol Depend. 2016 Nov 01;168:293-306
pubmed: 27614380
Chronic Dis Inj Can. 2012 Sep;32(4):186-93
pubmed: 23046800
Stat Med. 2009 Jan 30;28(2):205-20
pubmed: 18991332
Subst Abus. 2018;39(4):509-517
pubmed: 29958085
Acad Emerg Med. 2017 Apr;24(4):475-483
pubmed: 27763703
Int J Drug Policy. 2012 Jan;23(1):24-32
pubmed: 21719267
Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:68-77
pubmed: 31507029
Soc Psychiatry Psychiatr Epidemiol. 2017 Jul;52(7):877-886
pubmed: 28550519
Can J Psychiatry. 2007 Jul;52(7):426-33
pubmed: 17688006
PLoS One. 2015 Nov 04;10(11):e0140165
pubmed: 26536469
Psychiatr Q. 2016 Dec;87(4):713-728
pubmed: 26875101
Evid Based Spine Care J. 2014 Oct;5(2):74-6
pubmed: 25278880
J Urol. 2013 Jul;190(1):17-8
pubmed: 23608038
BMC Psychiatry. 2016 Jul 22;16:258
pubmed: 27450676
Can J Psychiatry. 2015 Dec;60(12):571-9
pubmed: 26720826
CMAJ. 2019 Jul 22;191(29):E804-E810
pubmed: 31332048
PLoS One. 2018 Aug 23;13(8):e0202028
pubmed: 30138449

Auteurs

Christophe Huỳnh (C)

University Institute on Addictions, 49987CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montréal, Québec, Québec.
Department of Psychiatry and Addiction, University of Montréal, Montréal, Québec, Canada.
School of Psychoeducation, University of Montréal, Montréal, Québec, Canada.
Recherche et Intervention sur les Substances Psychoactives - Québec, Trois-Rivières, Québec, Canada.
54470Institut National de Santé Publique du Québec, Québec, Canada.

Steve Kisely (S)

Department of Community Health and Epidemiology, 12361Dalhousie University, Halifax, Nova Scotia, Canada.
School of Medicine, University of Queensland, Queensland, Australia.

Louis Rochette (L)

54470Institut National de Santé Publique du Québec, Québec, Canada.

Éric Pelletier (É)

54470Institut National de Santé Publique du Québec, Québec, Canada.

Kenneth B Morrison (KB)

151965Alberta Health, Edmonton, Alberta, Canada.

Shelley Li (S)

151965Alberta Health, Edmonton, Alberta, Canada.

Gareth Hopkin (G)

Institute of Health Economics & University of Alberta, Edmonton, Alberta, Canada.
Health Technology Wales, 1029NHS Wales/GIG Cymru, Cardiff, Wales, UK.

Mark Smith (M)

Manitoba Centre for Health Policy, Rady Faculty of Health Sciences, 50023University of Manitoba, Winnipeg, Manitoba, Canada.

Charles Burchill (C)

Manitoba Centre for Health Policy, Rady Faculty of Health Sciences, 50023University of Manitoba, Winnipeg, Manitoba, Canada.

Elizabeth Lin (E)

7978Centre for Addiction & Mental Health, Toronto, Ontario, Canada.
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
ICES, Toronto, Ontario, Canada.

Mark Asbridge (M)

Department of Community Health and Epidemiology, 12361Dalhousie University, Halifax, Nova Scotia, Canada.

Didier Jutras-Aswad (D)

University Institute on Addictions, 49987CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montréal, Québec, Québec.
Department of Psychiatry and Addiction, University of Montréal, Montréal, Québec, Canada.
Research Centre, 5622Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

Alain Lesage (A)

University Institute on Addictions, 49987CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montréal, Québec, Québec.
Department of Psychiatry and Addiction, University of Montréal, Montréal, Québec, Canada.
54470Institut National de Santé Publique du Québec, Québec, Canada.
25443Research Centre of the Montréal Mental Health University Institute, Montréal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH